• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

    11/21/24 8:00:00 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLM alert in real time by email

    FOSTER CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it will affect a 1-for-100 reverse share split ("Reverse Share Split") of its class A ordinary shares, par value $0.0001 per share ("Old Shares"), which will become effective at 12:01a.m. Eastern Time on Monday, November 25, 2024 (the "Effective Time"). The Company's new class A ordinary shares, par value $0.01 per share ("New Shares") will begin trading on a split-adjusted basis on the Nasdaq Stock Market at the open of trading on November 25, 2024, under the existing symbol "APLM" and new CUSIP number G0411D123.

    At the Company's Extraordinary General Meeting of Shareholders held on November 14, 2024 (the "Meeting"), the Company's shareholders approved a proposal to effect a reverse share split of the Company's Old Shares at a ratio of not less than twenty-five to one (25:1) and up to one hundred to one (100:1), with such ratio and the implementation and timing of such Reverse Share Split to be determined by the Company's Board of Directors in its sole discretion. The Board of Directors has now approved the implementation of a one hundred to one (100:1) Reverse Share Split with the timing described above. The Company's shareholders also approved the proposal to increase the authorized share capital, if the Reverse Share Split is implemented, from 6,500,000 shares to 130,000,000 shares comprising (i) 100,000,000 New Shares, (ii) 20,000,000 class B ordinary shares and (iii) 10,000,000 preference shares, with a par value of US$0.01 each.   As a result of the Reverse Share Split, every 100 Old Shares issued and outstanding as of the Effective Time will automatically be combined into one New Share. No fractional shares will be issued as a result of the Reverse Share Split.

    The terms of outstanding warrants and equity-based awards (including exercise price and number of shares issuable thereunder) will be proportionately adjusted, in accordance with the terms of the applicable agreement. Specifically, every 100 Old Shares that may be purchased pursuant to the exercise of warrants prior to the Effective Time represent one New Share that may be purchased pursuant to such warrants following the Effective Time. The exercise price for each public warrant following the Effective Time will equal the product of $11.50, the warrant price immediately prior to the Effective Time, and a fraction (x) the numerator of which shall be one hundred (100), and (y) the denominator of which shall be one (1), which the numerator and denominator are based on the Reverse Share Split ratio; accordingly, the exercise price for the Company's warrants trading under the symbol "APLMW" will be $1,150.00. The CUSIP number for the Company's warrants will not change.

    About Apollomics Inc.

    Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics' lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and over 10 other countries. For more information, please visit www.apollomicsinc.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release includes statements that constitute "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of present or historical fact included in this press release, regarding the Company's strategy, prospects, plans and objectives are forward-looking statements, including statements about the Company's Reverse Share Split. When used in this press release, the words "could," "should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States and China affecting Apollomics' operations and the continued listing of Apollomics' securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics' oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to protect Apollomics' intellectual property; (v) breaches in data security; (vi) the risk that Apollomics may not be able to develop and maintain effective internal controls; (vii) unfavorable changes to the regulatory environment; and (viii) those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2023, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission ("SEC") under the heading "Risk Factors" and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC's website at www.sec.gov. Forward-looking statements speak only as of the date made by the Company. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.

    Investor Contact:

    Eric Ribner

    LifeSci Advisors, LLC

    (646) 751-4363

    [email protected]



    Primary Logo

    Get the next $APLM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What is the announcement made by Apollomics regarding its shares?

      Apollomics has announced a 1-for-100 reverse share split of its class A ordinary shares, effective on November 25, 2024.

    • What did the shareholders approve regarding the reverse share split?

      The shareholders approved the reverse share split at a ratio of not less than 25:1 and up to 100:1. The Board of Directors decided to implement the maximum ratio of 100:1.

    • How will the reverse share split affect existing shareholders?

      The reverse share split means that every 100 old shares will be combined into one new share, with the new shares having a par value of $0.01 each.

    • What will happen to the exercise price of existing warrants after the reverse share split?

      Following the split, the exercise price for each public warrant will be adjusted to $1,150.00, based on the product of the old price and the reverse split ratio.

    • What is the main focus of Apollomics as a biopharmaceutical company?

      Apollomics is focusing on developing oncology therapies, with its lead drug candidate being vebreltinib, a selective c-Met inhibitor currently in phase 2 trials.

    Recent Analyst Ratings for
    $APLM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APLM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

      Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for the vebreltinib development program, including in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification$9.8 million in cash and cash equivalents as of December 31, 2024, in conjunction with LaunXP upfront payment, pipeline focus and expense reductions expected to provide cash runway into the first quarter of 2026 FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics"), a late-stage clinical bio

      4/3/25 4:05:00 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

      LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer ("NSCLC")Apollomics to receive upfront payments of $10 million, and is eligible for pre-commercial milestones up to $50 million, and royalties on net product sales FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and LaunXP International Co.,

      3/31/25 8:00:32 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

      FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan. The Phase 3 trial was a randomized, double-blinded bridging trial to evaluate the safety and efficacy of uproleselan administered with chemotherapy versus chemotherapy alone in patients with relapsed or refract

      12/20/24 8:00:00 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Apollomics Inc.

      SC 13D/A - Apollomics Inc. (0001944885) (Subject)

      8/15/24 4:38:25 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Apollomics Inc. (Amendment)

      SC 13G/A - Apollomics Inc. (0001944885) (Subject)

      5/30/24 4:15:08 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Apollomics Inc. (Amendment)

      SC 13D/A - Apollomics Inc. (0001944885) (Subject)

      5/22/24 7:32:01 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLM
    Financials

    Live finance-specific insights

    See more
    • Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

      Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-

      3/28/24 7:00:00 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

      FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets. Apollomics' management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The conference call will be available on Apollomics' website, www.apollomicsinc.com, under the Investors section and will be archived there for approximately 90 days. The co

      3/26/24 8:00:00 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

      Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and investments at June 30, 2023; Cash runway to mid-year 2024 Debuted as a publicly traded targeted oncology company March 30, 2023 Management to host conference call Monday, October 2, 2023 at 8:30 a.m. ET FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today annou

      9/28/23 4:17:57 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLM
    SEC Filings

    See more
    • SEC Form 20-F filed by Apollomics Inc.

      20-F - Apollomics Inc. (0001944885) (Filer)

      4/3/25 4:51:31 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Apollomics Inc.

      6-K - Apollomics Inc. (0001944885) (Filer)

      4/3/25 4:40:55 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Apollomics Inc.

      6-K - Apollomics Inc. (0001944885) (Filer)

      3/31/25 8:00:45 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care